In 2018 more people received treatment for tuberculosis than ever before, largely due to improvements in detection and diagnosis, according to the latest Global Tuberculosis Report from the WHO.
New research has uncovered that Mycobacterium tuberculosis releases an antacid that remodels phagosomes, preventing immune cells from destroying the bacteria.
The US FDA has approved Pretomanid tablets in combination with bedaquiline and linezolid for the treatment of specific types of drug-resistant pulmonary tuberculosis.
A novel phage-based blood assay has demonstrated its potential for identifying people at high-risk of developing tuberculosis, in addition to diagnosing established cases.
Innate lymphoid cells, a relatively newly discovered class of immune cells, play a pivotal role in controlling early tuberculosis infection, according to new research.
Tuberculosis, or TB, is the leading infectious killer globally; in 2017 there were 10 million cases of the disease and 1.6 million deaths. Recent years have seen huge progress in research but more action is still needed, so where did the story start?
The latest report from the ECDC and WHO has analysed the 2017 data for the European region, suggesting that despite an overall decline in the number of cases, TB remains a major public health challenge.
Dr. Suvanand Sahu, Deputy Executive Director, at the Stop TB Partnership, reflects on the UNHLM on TB outlining the progress that was made and what more needs to be done.
In line with World Tuberculosis Day 2019, we are hosting a Twitter chat #TalkTB with prominent experts in the field of tuberculosis on Thursday March 21 at 11:00 EDT / 15:00 GMT.
Find out more about the headlines from the Conference on Retroviruses and Opportunistic Infections 2019 (CROI) in our round-up of conference news.
